Skip to content

US · GDRX · MEDICAL - HEALTHCARE INFORMATION SERVICES

GoodRx Holdings, Inc. (GDRX) intrinsic value and stock valuation

$2.92as of 2026-11-21 · Mkt cap 1.28B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GoodRx Holdings, Inc. DCF and intrinsic value

InvestorsCraft values GDRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from GDRX’s statements →

GoodRx Holdings, Inc. Graham Number

Graham Number: $1.82d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Santa Monica, CA 90404 goodrx.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$796.9M+7.7% 5y CAGRd
20162025
Net income
$30.4M
20162025
Free cash flow
$164.4M+11.5% 5y CAGRd
20182025
Total equity
$616.3M-2.8% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$796.9M$792.3M$750.3M$766.6M$745.4M
Operating income$87.5M$65.9M-$-27.01M$1.74M$13.4M
Net income$30.4M$16.4M-$-8.87M-$-32.83M-$-25.25M
EPSd$85.3K$41.8K-$-21.62K-$-79.52K-$-61.59K
Operating cash flow$167.9M$183.9M$138.3M$146.8M$178.8M
Capital expenditure-$-3.52M-$-70.35M-$-55.77M-$-55.21M-$-34.46M
Free cash flow$164.4M$113.6M$82.5M$91.6M$144.3M
Total assets$1.4B$1.39B$1.59B$1.6B$1.61B
Total debt$542.8M$543.4M$711.1M$717M$702.3M
Net debt$281M$95M$38.8M-$-40.14M-$-238.78M
Total equity$616.3M$724.7M$762M$814.8M$831.7M
Cash and short-term investments$261.8M$448.4M$672.3M$757.2M$941.1M
Income statement
20252024202320222021
Revenue$796.9M$792.3M$750.3M$766.6M$745.4M
Cost of revenue$57.6M$48.2M$66.9M$65.1M$46.7M
Gross profit$739.3M$744.1M$683.3M$701.5M$698.7M
Research and development expenses$121M$123.8M$135.8M$143.1M$125.9M
Selling, general and administrative expenses$445.5M$485M$466.8M$502.4M$524.9M
Other expenses$85.2M$69.5M$107.7M$54.2M$34.5M
Operating expenses$651.8M$678.3M$710.4M$699.7M$685.3M
Cost and expenses$709.4M$726.5M$777.3M$764.8M$732M
Interest income$10.9M$23.3M$32.2M$9.27M$60K
Interest expense$42.6M$52.9M$56.7M$34.2M$23.6M
Depreciation and amortization$85.2M$69.5M$107.7M$54.2M$34.5M
Ebitda$184.4M$153.9M$108.8M$65.2M$48M
Operating income$87.5M$65.9M-$-27.01M$1.74M$13.4M
Total other income/expenses, net-$-30.95M-$-34.39M-$-28.57M-$-24.97M-$-23.58M
Income before tax$56.5M$31.5M-$-55.57M-$-23.23M-$-10.18M
Income tax expense$26.1M$15.1M-$-46.7M$9.6M$15.1M
Net income$30.4M$16.4M-$-8.87M-$-32.83M-$-25.25M
Weighted average shares outstanding$356.3M$385.7M$410.3M$412.9M$410M
Weighted average diluted shares outstanding$357M$392.2M$410.3M$412.9M$410M
Balance sheet
20252024202320222021
Cash and short-term investments$261.8M$448.4M$672.3M$757.2M$941.1M
Net receivables$254.9M$160.8M$160M$121.7M$126.4M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$643.1M$659.3M$872.8M$919.7M$1.09B
Property, plant and equipment, net$41.1M$40.5M$45.9M$55.7M$49.3M
Goodwill and intangible assets$633.7M$587.7M$567.1M$602.1M$463.5M
Long-term investments$0.00$0.00$0.00$19M$4M
Total non-current assets$761M$728.8M$716M$685M$518.8M
Total assets$1.4B$1.39B$1.59B$1.6B$1.61B
Accounts payable$19.4M$14.1M$36.3M$17.7M$17.5M
Short-term debt$9.75M$10.6M$15M$11.1M$12.9M
Deferred revenue$6.71M$6.04M$7.11M$7.88M$6.87M
Total current liabilities$246M$123.9M$122.6M$76.3M$81.1M
Long-term debt$533.1M$532.8M$696.1M$705.9M$689.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$541.8M$539.5M$704.3M$713.5M$694.8M
Capital lease obligations$54.5M$51.7M$54.6M$58.2M$39.4M
Total liabilities$787.8M$663.4M$826.8M$789.8M$776M
Common stock$30K$40K$40K$40K$40K
Retained earnings-$-1.41B-$-1.44B-$-1.46B-$-1.45B-$-1.42B
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$616.3M$724.7M$762M$814.8M$831.7M
Total investments$0.00$0.00$0.00$19M$4M
Total debt$542.8M$543.4M$711.1M$717M$702.3M
Net debt$281M$95M$38.8M-$-40.14M-$-238.78M
Cash flow statement
20252024202320222021
Net income$30.4M$16.4M-$-8.87M-$-32.83M-$-25.25M
Depreciation and amortization$85.2M$69.5M$111.8M$54.2M$34.5M
Stock-based compensation$76.6M$99M$104.8M$120.2M$160.5M
Change in working capital-$-56.44M$2.09M-$-21.94M-$-20.29M-$-11.8M
Accounts receivable-$-88.02M-$-2.33M-$-26.47M$1.38M-$-43.95M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.1M-$-21.24M$17.5M-$-870K$4.21M
Net cash provided by operating activities$167.9M$183.9M$138.3M$146.8M$178.8M
Investments in property, plant and equipment-$-2.28M-$-1.24M-$-1.04M-$-3.97M-$-4.57M
Acquisitions, net-$-30M$0.00$0.00-$-155.28M-$-144.28M
Net cash used for investing activities-$-119.96M-$-70.35M-$-55.77M-$-210.5M-$-178.73M
Common stock issued$0.00$0.00$0.00$0.00$35M
Common stock repurchased-$-206.94M-$-158.84M-$-103.97M-$-101.72M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-234.47M-$-337.5M-$-167.4M-$-120.23M-$-30.53M
Net change in cash-$-186.53M-$-223.95M-$-84.87M-$-183.94M-$-30.48M
Cash at end of period$261.8M$448.4M$672.3M$757.2M$941.1M
Operating cash flow$167.9M$183.9M$138.3M$146.8M$178.8M
Capital expenditure-$-3.52M-$-70.35M-$-55.77M-$-55.21M-$-34.46M
Free cash flow$164.4M$113.6M$82.5M$91.6M$144.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GoodRx Holdings, Inc.

        GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.

        CEO
        Wendy Barnes
        Employees
        697
        Beta
        1.61

        Explore

        Frequently asked questions

        What is the intrinsic value of GoodRx Holdings, Inc. (GDRX)?

        GoodRx Holdings, Inc. (GDRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GDRX undervalued?

        GDRX trades at a price of $2.92 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.